PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Income Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Selling, General & Admin	3.94	6.11	5.99	3.7	2.71
Research & Development	0.44	0.41	0.47	0.69	0.92
Operating Expenses	4.38	6.52	6.46	4.39	3.62
Operating Income	-4.38	-6.52	-6.46	-4.39	-3.62
Interest Expense	-	-	-	-0	-0
Interest & Investment Income	1.42	3.4	1.94	0.16	-
Other Non Operating Income (Expenses)	9.11	5.45	0.2	-0	-0
EBT Excluding Unusual Items	6.15	2.33	-4.32	-4.24	-3.63
Gain (Loss) on Sale of Investments	26.53	-	-	-	-
Asset Writedown	-	-2	-	-	-
Legal Settlements	-2.02	-	-	-	-
Other Unusual Items	-	-	-	-	0.08
Pretax Income	30.66	0.33	-4.32	-4.24	-3.55
Net Income	30.66	0.33	-4.32	-4.24	-3.55
Preferred Dividends & Other Adjustments	7.29	17.57	-	-	-
Net Income to Common	23.36	-17.24	-4.32	-4.24	-3.55
Net Income Growth	9084.98%	-	-	-	-
Shares Outstanding (Basic)	7	10	19	16	1
Shares Outstanding (Diluted)	7	10	19	16	1
Shares Change (YoY)	-23.50%	-50.84%	25.56%	971.73%	60.24%
EPS (Basic)	3.19	-1.80	-0.22	-0.27	-2.45
EPS (Diluted)	3.19	-1.80	-0.22	-0.27	-2.45
EBIT	-4.38	-6.52	-6.46	-4.39	-3.62

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q